Rapid Micro Biosystems Enters into Five-Year, $45 Million Term Loan Facility with Trinity Capital Inc.

Core Viewpoint - Rapid Micro Biosystems has secured a five-year, $45 million term loan facility with Trinity Capital to enhance its financial position and support long-term growth initiatives [1][3]. Financial Details - The loan facility consists of four tranches: $20 million drawn at closing, $20 million available upon achieving specific milestones, and a $5 million tranche at the lender's discretion [3][7]. - The interest rate on the loan is initially set at 11.5% per annum, with a 36-month interest-only period [3]. Use of Proceeds - Proceeds from the loan will be allocated for general corporate purposes, including global expansion of the Growth Direct system and investments in manufacturing efficiencies and cost reduction [2][3]. Company Overview - Rapid Micro Biosystems specializes in automation solutions for the healthcare sector, focusing on the efficient manufacturing and release of products like biologics and vaccines [5]. - The flagship Growth Direct system automates microbial quality control testing, improving speed, accuracy, and compliance in pharmaceutical manufacturing [4][5].